TNGX Q3 2021 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+160.3% YoY

Gross Profit

-$15M-223.0% margin

Operating Income

-$20M-288.3% margin

Net Income

-$20M-288.6% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-62.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$530M

Total Liabilities

$165M

Stockholders' Equity

$365M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	-$11M	+160.3%
Gross Profit	-$15M	-$24M	+37.6%
Operating Income	-$20M	-$27M	+26.9%
Net Income	-$20M	-$27M	+26.9%

Revenue Segments

License Revenue

$11M62%

Collaboration Revenue

$7M38%